Related Experiment Video
Updated: Jun 19, 2026
07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Biomarkers: in combination they may do better.
Arthritis Research & Therapy
|November 6, 2009
Summary
Biomarkers are crucial for understanding osteoarthritis (OA), a common disabling condition. Combining existing biomarkers shows promise for improving accuracy in OA status, prognosis, and treatment response assessment.
Area of Science:
- Biomarker discovery and development
- Osteoarthritis (OA) research
- Musculoskeletal disease mechanisms
Background:
- Osteoarthritis (OA) is a prevalent disabling condition in older adults, contributing significantly to morbidity.
- The etiology of OA involves complex interactions between cartilage, bone, and synovium, with ongoing debate regarding the primary contributing tissue.
- Current research focuses on identifying reliable biomarkers for OA characterization, prognosis, and treatment monitoring.
Discussion:
- The development of abnormalities in cartilage, bone, and synovium occurs concurrently in OA.
- A comprehensive biomarker may need to reflect the integrated pathological processes across multiple tissues.
- Combining existing biomarkers is a promising strategy to enhance diagnostic and prognostic accuracy.
Key Insights:
- Biomarkers are increasingly important in osteoarthritis research.
- Identifying biomarkers that capture the concerted pathological changes in OA tissues is a key goal.
- Synergistic approaches using multiple biomarkers may improve OA assessment.
Outlook:
- Continued efforts to discover and validate novel OA biomarkers are essential.
- Combining existing biomarkers offers a pragmatic approach to improve OA status and treatment response characterization.
- Future research may focus on multi-analyte panels reflecting OA's complex pathophysiology.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...